Increased sputum amino acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pseudomonas aeruginosa may undergo a phenotypic change from the wild (prototrophic) type to an auxotrophic phenotype in the course of respiratory infection in patients with cystic fibrosis. The clinical significance of this is unclear. A study was undertaken to investigate whether the presence of auxotrophs of P aeruginosa in the sputum of patients with cystic fibrosis correlated with severity of respiratory disease, and whether increased sputum concentrations of amino acids were associated with the emergence of these forms. METHODS: Sixty adult patients with cystic fibrosis, colonised by P aeruginosa, were recruited and baseline clinical data including lung function were recorded. Serial sputum samples were obtained before, during, and after infective exacerbations where possible. These samples were used for routine microbiological culture, assessment of auxotrophy of P aeruginosa, measurement of amino acid content, and neutrophil elastase assay. RESULTS: Auxotrophy was common in patients with cystic fibrosis and 20 (33%) had a mean percentage auxotroph count of more than 50% total cfu/ml. The mean percentage auxotroph count was inversely correlated with forced expiratory volume in one second (FEV(1); tau = -0.194, p = 0.031). The median sputum amino acid concentration of the group was 12.5 mmol/l (range 0.13-40.6). The mean amino acid concentration in 33 subjects during infective exacerbations was 18.2 mmol/l (95% CI 15.1 to 21.3) compared with 12.3 mmol/l (95% CI 9.8 to 14.8) when well (p = 0.001). The amino acid content of sputum was inversely correlated with FEV(1) (tau = -0.253, p = 0.005). CONCLUSIONS: P aeruginosa frequently exhibits auxotrophy in patients with cystic fibrosis, particularly in those with severe underlying pulmonary disease. The sputum amino acid content of patients with cystic fibrosis is high during infective exacerbations and correlates with pulmonary disease severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
POUW, E. M., SCHOLS, A. M. W. J., DEUTZ, N. E. P., & WOUTERS, E. F. M. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.3.9708097 · Cited by 114 · cited 1×
“This study adds to this by demonstrating an association between amino acid concentration and severity of pulmonary disease. There are a number of possible explanations for raised amino acid concentrations in the lungs of cystic fibrosis patients. It has been suggested that the concentration of amino acids in alveolar…”
Result
Cited by
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
Nutritional Cues Control Pseudomonas aeruginosa Multicellular Behavior in Cystic Fibrosis Sputum
Palmer, K. L., Aye, L. M., & Whiteley, M. (2007) · Journal of Bacteriology · doi:10.1128/jb.01138-07 · Cited by 651
Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis
Goss, C. H., & Burns, J. L. (2007) · Thorax · doi:10.1136/thx.2006.060889 · Cited by 445
Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis
Hauser, A. R., Jain, M., Bar-Meir, M., & McColley, S. A. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-10 · Cited by 411
Cystic Fibrosis Sputum Supports Growth and Cues Key Aspects of Pseudomonas aeruginosa Physiology
Palmer, K. L., Mashburn, L. M., Singh, P. K., & Whiteley, M. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.15.5267-5277.2005 · Cited by 402
Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung
Sriramulu, D. D., Lünsdorf, H., Lam, J. S., & Römling, U. (2005) · Journal of Medical Microbiology · doi:10.1099/jmm.0.45969-0 · Cited by 366
Hassett, D. J., Cuppoletti, J., Trapnell, B., Lymar, S. V., Rowe, J. J., Sun Yoon, S., Hilliard, G. M., Parvatiyar, K., Kamani, M. C., Wozniak, D. J., et al. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00152-7 · Cited by 313
Sousa, A., & Pereira, M. (2014) · Pathogens · doi:10.3390/pathogens3030680 · Cited by 279
NTM drug discovery: status, gaps and the way forward
Wu, M.-L., Aziz, D. B., Dartois, V., & Dick, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.04.001 · Cited by 276
Li, H., Luo, Y.-F., Williams, B. J., Blackwell, T. S., & Xie, C.-M. (2012) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2011.10.001 · Cited by 266
Bernier, S. P., Lebeaux, D., DeFrancesco, A. S., Valomon, A., Soubigou, G., Coppée, J.-Y., Ghigo, J.-M., & Beloin, C. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003144 · Cited by 262
Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung
Hogardt, M., & Heesemann, J. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2010.08.008 · Cited by 257
Bragonzi, A., Paroni, M., Nonis, A., Cramer, N., Montanari, S., Rejman, J., Di Serio, C., Döring, G., & Tümmler, B. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200812-1943oc · Cited by 255
Quinn, R. A., Lim, Y. W., Maughan, H., Conrad, D., Rohwer, F., & Whiteson, K. L. (2014) · mBio · doi:10.1128/mbio.00956-13 · Cited by 115
“aeruginosa metabolism and antimicrobial activity are dependent upon the presence of high concentrations of amino acids (24, 51, 52).”
BackgroundPleguezuelos-Manzano, C., Beenker, W. A. G., van Son, G. J. F., Begthel, H., Amatngalim, G. D., Beekman, J. M., Clevers, H., & den Hertog, J. (2023) · doi:10.1101/2023.03.11.532178 · Cited by 5
Metadata
- Authors
- Thomas, S. R.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2000-09-01
- Volume
- 55
- Issue
- 9
- Pages
- 795-797
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2118316262
- Cited by
- 127
- References
- 1
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.